試す 金 - 無料
Ayurveda gaining significant traction in global markets
Chronicle Pharmabiz
|November 27, 2025
DRIVEN by the growing demand for natural and holistic wellness products, Ayurveda is gaining significant traction in international markets.
The global Ayurveda market is estimated to be billions of dollars, with forecasts predicting strong double-digit growth over the coming decade.
One of the key drivers fuelling this growth is the increasing popularity of natural products. Consumers are seeking alternative, plant-based remedies, driving demand for Ayurvedic products. The Indian government is also promoting Ayurveda through a number of initiatives Moreover India's “Heal in India” initiative aims to integrate modern medicine with Ayurveda, attracting international patients.
To capitalize on this trend, Indian Ayurvedic companies are focusing on sustainable practices, organic sourcing, and eco-friendly packaging.
Growing awareness of herbal products
According to Dr DBA Narayana, CSO, Ayurvidye Trust, with many efforts by the Ayush Ministry and Government of India during and post Covid, there has been growing awareness and some acceptance for herbal based products including Ayurvedic products. However, one facet of this globally has not been extended and used to promote exports of ayurvedic medicines and products.
Qualified ayurvedic clinicians should consider using technology to make such video consultation possible, they need to identify simple classical medicines that can be recommended to the patients who consult them. Ayush Ministry should make list of Classical grantha preparation which have a high safety profile and liase with governments globally to initiate a process for" import of such medicines prescribed for personal use n some simple import regulations in that country that permit importation for personal use”, said Dr Narayana.
このストーリーは、Chronicle Pharmabiz の November 27, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Chronicle Pharmabiz からのその他のストーリー
Chronicle Pharmabiz
Home-grown CAR-T cell therapies gaining ground
INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.
4 mins
November 27, 2025
Chronicle Pharmabiz
NPPA extends price fixation on orthopaedic implants for 1 year
IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.
1 mins
November 27, 2025
Chronicle Pharmabiz
FICCI envisages it's Smart AAMs to boost healthcare
In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.
1 min
November 27, 2025
Chronicle Pharmabiz
DoP asked to bring policy for affordable drug pricing
THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.
1 mins
November 27, 2025
Chronicle Pharmabiz
Ramaiah emphasises need for bone health and osteoporosis diagnosis
RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.
2 mins
November 27, 2025
Chronicle Pharmabiz
Nathealth calls for action in 2026-27 Union Budget
NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.
1 mins
November 27, 2025
Chronicle Pharmabiz
Hotspots & growth opportunities in biomanufacturing
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
3 mins
November 27, 2025
Chronicle Pharmabiz
Omega Hospitals acquires Cytecare Hospitals
Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.
2 mins
November 27, 2025
Chronicle Pharmabiz
Devices sector hails withdrawal of QCOs
THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.
1 min
November 27, 2025
Chronicle Pharmabiz
'There is urgent need for tech-focused regulatory approach for med devices'
THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.
2 mins
November 27, 2025
Listen
Translate
Change font size
